Biotech
News Category
Helus Pharma Reports Fiscal 2026 Results, Phase 3 Trial for Major Depressive Disorder on Track
Helus Pharma announced fiscal 2026 financial results and progress in its Phase 3 trials for HLP003 in major depressive disorder, with topline data exp...
Soligenix Advances HyBryte as Potential First-Line CTCL Treatment with Promising FLASH Results
Soligenix's HyBryte shows statistically significant efficacy in treating early-stage cutaneous T-cell lymphoma, with potential to become the first app...
Aditxt Subsidiary Pearsanta Begins Enrollment in Clinical Study for Blood-Based Endometriosis Test
Pearsanta Inc., a subsidiary of Aditxt Inc., has initiated enrollment in a clinical study to validate its Mitomic Endometriosis Test, a non-invasive b...
NanoViricides to Present at PODD 2025 Conference, Highlighting Broad-Spectrum Antiviral Pipeline
NanoViricides will present updates on its antiviral drug pipeline and platform technologies at the PODD 2025 Conference, with lead candidate NV-387 ad...
Quantum BioPharma Announces Private Placement to Restore Voting Control
Quantum BioPharma's private placement of Class A shares aims to restore voting control to its founding entities, highlighting strategic moves to secur...
Oncotelic Therapeutics' Sapu003 Accepted for Presentation at 2025 San Antonio Breast Cancer Symposium
Oncotelic Therapeutics announced that its joint venture's investigational drug Sapu003, a novel formulation of everolimus, has been accepted for prese...
Lifordi Immunotherapeutics Presents Nonclinical Data on LFD-200 at ACR 2025 and Initiates Phase 1 Study in Rheumatoid Arthritis
Lifordi Immunotherapeutics announced the initiation of a Phase 1 study for its glucocorticoid antibody-drug conjugate LFD-200 in rheumatoid arthritis,...
Quantum BioPharma Announces Private Placement of Class A Multiple Voting Shares
Quantum BioPharma Ltd. disclosed a non-brokered private placement of up to 30 Class A multiple voting shares at $25 each, raising up to $750 for gener...
Cybin CMO to Speak at 2025 Milken Institute Future of Health Summit
Cybin's Chief Medical Officer will discuss the company's Phase 3 psychedelic treatment for major depressive disorder at a major health policy summit, ...
Cybin to Present at Guggenheim Healthcare Innovation Conference, Highlighting Progress in Psychedelic-Based Treatments for Mental Health
Cybin Inc., a Phase 3 clinical stage neuropsychiatry company, will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference, undersco...
HeartBeam Submits 12-Lead ECG Synthesis Software for FDA Clearance, Paving Way for Commercialization
HeartBeam Inc. has submitted its cable-free 12-lead ECG synthesis software for arrhythmia assessment to the FDA for 510(k) clearance, advancing toward...
Annovis Bio Completes Site Activation and First Patient Completions in Pivotal Phase 3 Alzheimer’s Trial
Annovis Bio announces that all 84 U.S. sites for its pivotal Phase 3 Alzheimer’s trial are activated and enrolling, with first patients completing the...
Oncotelic Venture Sapu Nano Receives Ethics Approval for Intravenous Everolimus Trial in Breast Cancer
Sapu Nano, a venture of Oncotelic Therapeutics, has received ethics committee approval in Australia to begin clinical trials for Sapu003, an injectabl...
NanoViricides Receives Regulatory Approval to Begin Phase II Trial of NV-387 for MPox in the DRC
NanoViricides has received approval from the DRC’s regulatory agency to start a Phase II trial of its broad-spectrum antiviral NV-387 for MPox, markin...
Cybin Inc. Reports Q2 2025 Results and Advances Late-Stage Neuropsychiatry Programs
Cybin Inc. reported strong Q2 results and progress in late-stage trials for depression and anxiety treatments, highlighting key data readouts expected...
Cybin to Present at Jefferies Global Healthcare Conference, Highlighting Progress in Psychedelic-Based Mental Health Treatments
Cybin Inc., a Phase 3 clinical-stage neuropsychiatry company, will present at the upcoming Jefferies Global Healthcare Conference, underscoring its ad...
Soligenix Reaches Enrollment Milestone for Interim Analysis in Phase 3 FLASH2 Study of HyBryte for Cutaneous T-Cell Lymphoma
Soligenix completed enrollment of 50 patients for the interim analysis in its Phase 3 FLASH2 study of HyBryte, with topline data expected in the secon...
Parent Challenges Myth Linking Vaccines to Autism, Urges Focus on Scientific Evidence
A parent of an autistic child, Greg Scaduto, publicly refutes the unfounded claims that vaccines cause autism, emphasizing the harm of such misinforma...
NRx Pharmaceuticals Reports Q3 2025 Results, Advances Regulatory Programs for NRX-100 and NRX-101
NRx Pharmaceuticals reported its first revenue and key regulatory progress for NRX-100 and NRX-101, including Fast Track status, Expanded Access, and ...
Stonegate Updates Coverage on Incannex Healthcare Inc., Highlighting Progress in OSA Treatment and Regulatory Planning
Stonegate Capital Partners' updated coverage on Incannex Healthcare Inc. emphasizes the significance of Phase 2 data for IHL-42X in obstructive sleep ...
Oncotelic Therapeutics Highlighted in BioMedWire Editorial on Biotech Valuation Trends
Oncotelic Therapeutics is preparing for a fair-value remeasurement of its 45% stake in GMP Bio, which could signal real scientific and commercial prog...
HyBryte and Federal Policy: Addressing Rare Diseases in an Aging America
The convergence of an aging population, high prevalence of rare diseases, and new federal health policy initiatives underscores the urgency of develop...
Soligenix's HyBryte for CTCL Highlighted in BioMedWire Editorial on Rare Disease Policy
A BioMedWire editorial examines the growing burden of rare diseases and the need for new therapies, spotlighting Soligenix's late-stage HyBryte for cu...
Quantum BioPharma's Lucid-MS Offers New Hope for Multiple Sclerosis Treatment
Quantum BioPharma Ltd. is featured in a BioMedWire editorial highlighting the limitations of current MS therapies and the potential of its drug candid...
Kairos Pharma Wins Clinical Trials Arena R&D Award for Advanced Prostate Cancer Therapy
Kairos Pharma's ENV-105, a novel CD105-targeting antibody, receives recognition for its potential to overcome treatment resistance in metastatic castr...
Soligenix Announces Publication of Positive Phase 2a Data for SGX945 in Behçet’s Disease
Soligenix published positive Phase 2a results for SGX945 (dusquetide) in treating aphthous ulcers associated with Behçet’s Disease, showing comparable...
Soligenix Reports Extended Positive Results from Phase 2a Psoriasis Study of SGX302
Soligenix announced extended top-line results from its Phase 2a clinical trial of SGX302 in mild-to-moderate psoriasis, showing clinical improvements ...
Quantum BioPharma Completes 180-Day Toxicity Studies for Lucid-MS, Advancing Multiple Sclerosis Treatment
Quantum BioPharma Ltd. announced the completion of chronic toxicity and toxicokinetic studies for Lucid-MS, a key step toward filing an IND with the F...
Fifty 1 Labs Clarifies No Partnership with LUNR Aerospace
Fifty 1 Labs (OTC: FITY) issued a clarification stating no formal partnership or collaboration has ever existed with LUNR Aerospace, and there is no c...
Tonix Pharmaceuticals to Present at January Investor Conferences, Highlighting Pipeline Progress
Tonix Pharmaceuticals announced its management will present at two January conferences, showcasing its marketed products and development pipeline, inc...
Tonix Pharmaceuticals to Present at Key January Investor Conferences, Highlighting Pipeline and Marketed Products
Tonix Pharmaceuticals announced its participation in two major January investor conferences, where management will discuss the company's neuroscience ...
Soligenix Reports Positive Phase 2 Data for SGX945 in Behçet's Disease
Soligenix announced positive top-line results from a phase 2a trial of SGX945 (dusquetide) for aphthous ulcers in Behçet's disease, a rare inflammator...
GeoVax Highlights 2026 as a Pivotal Year with Multiple Clinical, Regulatory, and Manufacturing Milestones
GeoVax Labs outlines 2026 as a transformative year driven by late-stage progress across its portfolio, including a pivotal Phase 3 trial for GEO-MVA, ...
Lantern Pharma Receives FDA Orphan Drug Designation for LP-284 in Soft Tissue Sarcomas
Lantern Pharma (NASDAQ: LTRN) announced FDA Orphan Drug Designation for LP-284 in soft tissue sarcomas, expanding its synthetic lethal mechanism into ...
HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer to Drive Commercial Expansion
HeartBeam Inc. (NASDAQ: BEAT) appointed Bryan Humbarger as chief commercial officer to lead the commercial launch of its FDA-cleared HeartBeam System ...
Drug Delivery Innovation Emerges as Key Frontier in Oncology
The article highlights how advanced drug delivery systems, such as Oncotelic Therapeutics' Deciparticle platform, are gaining traction as a cost-effec...
Soligenix Advances HyBryte as a Targeted Photodynamic Therapy for Early-Stage CTCL
Soligenix is developing HyBryte, a visible light-activated photodynamic therapy, to address critical gaps in treating early-stage cutaneous T-cell lym...
Tonix Pharmaceuticals Presents Positive Phase 3 Data for TONMYA in Fibromyalgia at Non-Opioid Pain Summit
Tonix Pharmaceuticals announced positive Phase 3 results for TONMYA, a non-opioid treatment for fibromyalgia, showing significant pain reduction and i...
Soligenix Advances HyBryte(TM) as a Novel Treatment for Cutaneous T-Cell Lymphoma, Addressing Unmet Needs in Rare Cancer Care
Soligenix is developing HyBryte(TM) (SGX301), a synthetic hypericin-based photodynamic therapy, to improve treatment tolerability and quality of life ...
Quantum BioPharma Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
Quantum BioPharma is progressing its novel MS therapy Lucid-MS to Phase 2 trials after positive Phase 1 results, offering a potential shift from immun...
Phio Pharmaceuticals Selected as B2i Digital Featured Company, Reports Promising Phase 1b Data in cSCC
Phio Pharmaceuticals' Phase 1b trial demonstrates approximately 65% pathological response in cutaneous squamous cell carcinoma with no serious adverse...
Helix BioPharma Presents CEACAM6-Directed ADC Data at World ADC London, Highlighting a Novel Targeted Therapy Approach
Helix BioPharma presented new data on its CEACAM6-directed antibody-drug conjugate at the World ADC London conference, demonstrating a tumor-selective...
Soligenix’s SGX945 Shows Promise in Phase 2 Trial for Behçet’s Disease Aphthous Ulcers
Soligenix reported positive top-line results from its Phase 2a trial of SGX945 for Behçet’s disease, highlighting a novel immune-modulating approach t...
LIXTE Biotechnology Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment
LIXTE Biotechnology is advancing LB-100, a novel PP2A inhibitor designed to enhance the efficacy of existing cancer therapies, addressing resistance a...
Oragenics Plots 2026 Milestones for Intranasal Concussion Therapy ONP-002
Oragenics Inc. outlines 2026 development milestones for its intranasal neurosteroid ONP-002, advancing toward Phase 2a trials in Australia for concuss...
Study Reveals Mechanism Behind Breast Cancer Brain Metastasis, Opening New Treatment Avenues
A multinational study led by Israeli researchers identifies why certain breast cancers metastasize to the brain, potentially leading to new therapies ...
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
Oncotelic Therapeutics is highlighted in a BioMedWire editorial as its late-stage oncology and CNS programs align with the growing trend in biotech M&...
Silo Pharma Receives Japan Patent Allowance for SPC-15 PTSD Candidate
Silo Pharma announced a Japan patent allowance for its lead asset SPC-15, an intranasal PTSD treatment, strengthening its intellectual property portfo...